The PennZone

International Collaboration Aims to Ensure More Equitable Access to Transformative Personalized Cancer Therapy

PHILADELPHIA, May 23, 2022 /PRNewswire/ -- Penn Medicine and Children's Hospital of Philadelphia (CHOP), who together pioneered the research and development of the world's first personalized cellular therapy for cancer — also known as CAR T cell therapy — have announced plans with Costa Rica's CCSS, or the Caja Costarricense de Seguro Social (Social Security Program), to facilitate CAR T research in Costa Rica. The effort is a step toward global equity in clinical research opportunities involving the use of CAR T cell therapies, which represent a leading-edge approach to cancer care not widely available across the world.

More on The PennZone

• PRÝNCESS Builds Anticipation With "My Nerves" — A Girls-Girl Anthem
• Arbutus Medical Raises C$9.3M to Accelerate Growth of Surgical Workflow Solutions Outside the OR
• From Sleepless Nights to Sold-Out Drops: Catch Phrase Poet's First Year Redefining Motivational Urban Apparel
• Now Live on Kickstarter: The Bottle That Chills and Purifies Any Freshwater — and Donates One for Every 10 Backers
• How Specialized Game Development Services Are Powering the Next Wave of Interactive Entertainment

---

Show All News | Report Violation